GeneDx Holdings (WGS) Equity Average (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of Equity Average data on file, last reported at $281.2 million in Q1 2026.

• Equity Average for Q1 2026 came in at $281.2 million, up 11.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $281.2 million (up 11.87% YoY), and the FY2025 annual result was $276.7 million, up 16.94% from the prior year.
• Equity Average declined to $281.2 million in Q1 2026 per WGS's latest filing, from $300.2 million in the prior quarter.
• Over five years, Equity Average peaked at $599.3 million in Q3 2022 and troughed at $199.3 million in Q3 2024.
• A 5-year average of $305.6 million and a median of $281.2 million in 2026 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2023: Equity Average soared 783.01% in 2022, then plunged 54.08% in 2023.
• A 5-year view of Equity Average shows it stood at $407.5 million in 2022, then tumbled by 40.83% to $241.1 million in 2023, then declined by 6.74% to $224.9 million in 2024, then soared by 33.51% to $300.2 million in 2025, then slipped by 6.35% to $281.2 million in 2026.
• Business Quant data shows WGS's Equity Average at $281.2 million in Q1 2026, $300.2 million in Q4 2025, and $284.7 million in Q3 2025.